Drug or treatment

Remibrutinib clinical trials

• 16Clinical trials
• 43Countries

Newest trials

All recruiting trials (16)

• BTK inhibitor remibrutinib in hidradenitis suppurativa shows how it works in adults

  This phase 1 trial tests whether remibrutinib can safely affect HS in adults with moderate to severe disease.

  Recruiting at 2 sites Phase 1 Novartis · San Diego, California and 1 other locations · NCT07855276

• Remibrutinib and omalizumab-based treatment approach for adults with chronic spontaneous urticaria not well controlled by antihistamines

  This trial tests a sequencing plan using remibrutinib and omalizumab to see if it helps adults with chronic spontaneous urticaria that isn’t well controlled by second-generation antihistamines.

  Recruiting at 10 sites Phase 3 Novartis · London, Ontario and 9 other locations · NCT07816328

• Remibrutinib for Severe Chronic Pruritus of Unknown Origin in Adults

  We’re testing whether remibrutinib can help adults with severe, unexplained itching that hasn’t gone away with moisturizers.

  Recruiting at 12 sites Phase 3 Novartis · Fremont, California and 11 other locations · NCT07811869

• Remibrutinib for IgE-mediated peanut, milk, and egg allergy

  This study tests whether remibrutinib can help people with peanut, milk, or egg allergies by comparing it to placebo over 52 weeks.

  Recruiting at 22 sites Phase 3 Novartis · Birmingham, Alabama and 21 other locations · NCT07768371

• Brain Imaging and Immune Changes During Remibrutinib in Relapsing MS

  This study tests how remibrutinib affects brain inflammation in people with relapsing MS who are also on ocrelizumab.

  Recruiting Washington University School of Medicine · St Louis, Missouri · NCT07758270

• Remibrutinib for Severe Chronic Pruritus of Unknown Origin

  This study tests whether remibrutinib can help adults with severe CPUO see if their itch improves compared with a placebo.

  Recruiting at 24 sites Phase 3 Novartis · Cullman, Alabama and 23 other locations · NCT07700056

• Remibrutinib for moderate-to-severe papulopustular rosacea

  A Phase 2 study tests whether remibrutinib can reduce inflammatory facial lesions in adults with moderate-to-severe papulopustular rosacea.

  Recruiting at 17 sites Phase 2 Novartis · El Paso, Texas and 16 other locations · NCT07681271

• Remibrutinib extension study for adults with moderate to severe hidradenitis suppurativa

  This extension study tests whether continuing remibrutinib is safe and helps skin symptoms in adults who completed prior HS trials.

  Recruiting at 61 sites Phase 3 Novartis · Birmingham, Alabama and 60 other locations · NCT07665437

• Remibrutinib in real-world care for Chronic Spontaneous Urticaria in Germany

  This study looks at how well and how safely remibrutinib works for adults with chronic spontaneous urticaria in real clinical practice after doctors decide to switch or escalate treatment.

  Recruiting Novartis · Düren · NCT07642557

• Open-label roll-over access to remibrutinib

  This program continues remibrutinib treatment and monitors long-term safety for people who were already benefiting from remibrutinib in a Novartis study but cannot get it outside the study.

  Recruiting at 46 sites Phase 3 Novartis · Sofia and 45 other locations · NCT07456891

• Remibrutinib for adults with chronic spontaneous urticaria in routine care

  This prospective US study will see if remibrutinib helps adults with chronic spontaneous urticaria in real-world clinical practice using patient-reported outcome questionnaires.

  Recruiting Novartis · East Hanover, New Jersey · NCT07408219

• Remibrutinib use in everyday US care for chronic spontaneous urticaria

  This US sub-study will test remibrutinib's real-world safety and effectiveness for adults with chronic spontaneous urticaria who are escalating or switching from second-generation H1 antihistamines.

  Recruiting Novartis · Kirksville, Missouri · NCT07358780

• Remibrutinib use in everyday clinical care for chronic spontaneous urticaria

  This project sees if remibrutinib helps adults with chronic spontaneous urticaria who need higher‑dose second‑generation antihistamines or are switching to remibrutinib.

  Recruiting Novartis · Kirksville, Missouri · NCT07358364

• Remibrutinib for secondary progressive multiple sclerosis

  This trial will try remibrutinib versus placebo to see if it slows disability progression in adults with secondary progressive multiple sclerosis.

  Recruiting at 296 sites Phase 3 Novartis · Birmingham, Alabama and 295 other locations · NCT07225504

• Evaluating Remibrutinib for Chronic Urticaria

  This study is testing if a new medication called remibrutinib can help adults with Chronic Urticaria feel better compared to a placebo over 12 weeks.

  Recruiting at 14 sites Phase 2 Novartis · North Miami Beach, Florida and 16 other locations · NCT06865651

• Remibrutinib after switching from ocrelizumab for relapsing multiple sclerosis

  This study will see if remibrutinib, a daily oral BTK inhibitor, keeps relapsing MS under control in people switching from ocrelizumab compared with continuing ocrelizumab.

  Recruiting at 128 sites Phase 3 Novartis · Scottsdale, Arizona and 130 other locations · NCT06846281

Quick answers

How many clinical trials of Remibrutinib are recruiting right now?

16, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 43 countries. The most sites are in United States (12 trials), Canada (8 trials), Germany (6 trials), Spain (6 trials), France (5 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 3: 8, Phase 2: 2, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →